Banseok Kim1, Hyo Jun Ahn1, Min Hyuk Choi1,2, Yongjung Park1. 1. Department of Laboratory Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea. 2. Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Anti-HCV assays are widely used as a screening tool for HCV infection. However, diagnostic performances and effective signal-to-cut-off ratios (S/COs) for predicting true HCV infections would vary according to the assays used. Thus, we evaluated the diagnostic performances of the new Elecsys Anti-HCV assay. METHODS: A total of 41 694 cases tested by the Elecsys Anti-HCV II assay (Roche Diagnostics, Germany) during January 2013 to December 2015 were retrospectively analyzed by comparing with the diagnosis on HCV infections determined by patients' medical records and results of laboratory tests. RESULTS: Excluding 62 cases with unclear history of HCV infection, 430 and 41 202 cases were respectively assorted as "true infection" and "no evidence of infection," and 99.85% of the initial results by the Elecsys assay were concordant with the diagnosis on HCV infection. Sensitivity, specificity, positive and negative predictive values were respectively 99.30%, 99.86%, 88.04%, and 99.99%, where the prevalence of the HCV infection was 1.0%. The area under the receiver operating characteristics curve value of the Elecsys assay was 0.9980 (95% confidence interval [CI]=0.9944 to 1.0017). The S/CO by the Elecsys assay for predictive of a true-positive ≥95% of the time was 19.0 (95% CI=15.0 to 25.1). CONCLUSION: The Elecsys Anti-HCV II assay showed excellent diagnostic performances, particularly in terms of sensitivity, specificity, and NPV. However, the results obtained by this assay with S/CO less than a certain value would need to be retested by HCV RNA PCR or another anti-HCV assay.
BACKGROUND: Anti-HCV assays are widely used as a screening tool for HCV infection. However, diagnostic performances and effective signal-to-cut-off ratios (S/COs) for predicting true HCV infections would vary according to the assays used. Thus, we evaluated the diagnostic performances of the new Elecsys Anti-HCV assay. METHODS: A total of 41 694 cases tested by the Elecsys Anti-HCV II assay (Roche Diagnostics, Germany) during January 2013 to December 2015 were retrospectively analyzed by comparing with the diagnosis on HCV infections determined by patients' medical records and results of laboratory tests. RESULTS: Excluding 62 cases with unclear history of HCV infection, 430 and 41 202 cases were respectively assorted as "true infection" and "no evidence of infection," and 99.85% of the initial results by the Elecsys assay were concordant with the diagnosis on HCV infection. Sensitivity, specificity, positive and negative predictive values were respectively 99.30%, 99.86%, 88.04%, and 99.99%, where the prevalence of the HCV infection was 1.0%. The area under the receiver operating characteristics curve value of the Elecsys assay was 0.9980 (95% confidence interval [CI]=0.9944 to 1.0017). The S/CO by the Elecsys assay for predictive of a true-positive ≥95% of the time was 19.0 (95% CI=15.0 to 25.1). CONCLUSION: The Elecsys Anti-HCV II assay showed excellent diagnostic performances, particularly in terms of sensitivity, specificity, and NPV. However, the results obtained by this assay with S/CO less than a certain value would need to be retested by HCV RNA PCR or another anti-HCV assay.
Authors: F Alborino; A Burighel; F-W Tiller; J van Helden; C Gabriel; A Raineri; R Catapano; H Stekel Journal: Med Microbiol Immunol Date: 2010-09-24 Impact factor: 3.402
Authors: Do Young Kim; In Hee Kim; Sook-Hyang Jeong; Yong Kyun Cho; Joon Hyoek Lee; Young-Joo Jin; Don Lee; Dong Jin Suh; Kwang-Hyub Han; Neung Hwa Park; Ha Yan Kang; Young Kul Jung; Young Seok Kim; Kyung-Ah Kim; Youn Jae Lee; Byung Seok Lee; Hyung Joon Yim; Heon Ju Lee; Soon Koo Baik; Won Young Tak; Sun Jae Lee; Woo Jin Chung; Sung-Kyu Choi; Eun-Young Cho; Jeong Heo; Dong Joon Kim; Byung-Cheol Song; Man Woo Kim; Jun Lee; Hee Bok Chae; Dae Hee Choi; Hwa Young Choi; Moran Ki Journal: Liver Int Date: 2013-01-29 Impact factor: 5.828
Authors: Juan I Esteban; Josef van Helden; Flora Alborino; Philippe Bürgisser; Cristina Cellerai; Giuseppe Pantaleo; Adolfo Eiras; Maria I Rodriguez; Valeria Ghisetti; Michael Gleich; Roland Imdahl; Claudia Kaiser; Petra Möller; Olaf Wetlitzky; Manuel Segovia; Harald Schennach; Annelies Mühlbacher Journal: J Med Virol Date: 2013-08 Impact factor: 2.327